For instance, survivors with cancers related to obesity often face higher risks for cancer recurrence and death—not just from ...

Slashing health care support for low-income Californians isn’t just a budget decision, it is a public health crisis in the ...

China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...

Doctors should provide high quality, evidence based care reflecting individual preferences and needs, regardless of weight, argue Juan Franco and colleagues Doctors have traditionally recommended ...

Riyadh – The capital city Riyadh hosted the launch of the “SAHEM” program, a distinguished national initiative aimed at ...

The increasing prevalence of overweight and obesity in China poses an urgent public health challenge requiring immediate ...

Spain’s ministry of health has asked Novo Nordisk for clarification about a controversial obesity awareness campaign which may have broken the country’s law on promoting prescription drugs. The ...

As rates of MASLD, which is linked to obesity and diabetes, rise, new therapies have emerged, but better diagnostic and ...

"These treatments are only available on the NHS under strict criteria, and access will be through specialist NHS weight ...

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant ...

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...